Sphingolipid Metabolism in Glioblastoma and Metastatic Brain Tumors: A Review of Sphingomyelinases and Sphingosine-1-Phosphate
Glioblastoma (GBM) is a primary malignant brain tumor with a dismal prognosis, partially due to our inability to completely remove and kill all GBM cells. Rapid tumor recurrence contributes to a median survival of only 15 months with the current standard of care which includes maximal surgical resec...
Main Authors: | Cyntanna C. Hawkins, Tomader Ali, Sasanka Ramanadham, Anita B. Hjelmeland |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/10/10/1357 |
Similar Items
-
Thematic Review Series: Sphingolipids. Nuclear sphingolipids: metabolism and signaling*
by: Robert W. Ledeen, et al.
Published: (2008-06-01) -
Sphingolipids: Important Players in Multiple Sclerosis
by: Ramona Halmer, et al.
Published: (2014-06-01) -
Re-Configuration of Sphingolipid Metabolism by Oncogenic Transformation
by: Anthony S. Don, et al.
Published: (2014-03-01) -
Sphingolipids and Diagnosis, Prognosis, and Organ Damage in Systemic Lupus Erythematosus
by: Olivia C. Harden, et al.
Published: (2020-09-01) -
Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma
by: Melinda N. Tea, et al.
Published: (2020-01-01)